Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Abstract

The present invention relates to compounds of formula (I) or formula (II) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) and said compound of formula II each comprises at least one ONOor ONO moiety; Ris C-Calkyl; Ris H, C-Calkyl, C-Ccycloalkyl, C-Calkoxy, C-Calkenyl; Ris C-Calkyl optionally substituted with C-Calkoxy, C-Ccycloalkyl, C-Calkenyl; Rand Rare each independently H or C-Calkyl optionally substituted with F, OH, ONO, ONO, COOH, C-Calkoxy, C-Ccycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homo-piperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with independently one or more R; Ris C-Calkyl optionally substituted with independently one or more halogen, OH, ONO, ONO, C-Calkoxy, C-Chaloalkoxy, COOR, NRR, C═NR; Ris H, or C-Calkyl optionally substituted with F, OH, ONO, ONO2, NRR; Rand Rare independently H, or C-Calkyl optionally substituted with ONO, ONO; Ris C-Calkyl optionally substituted with F, ONO, ONO; C-Ccycloalkyl; pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.